Navigation Links
Tolerx Presents Preclinical Data on Novel Cancer Immunotherapeutic, TRX518, a First-in-Class Anti-GITR Antibody
Date:2/9/2011

e escalation safety study in adults with Stage III/IV metastatic melanoma was initiated in December 2010 and is currently underway.

"We are very excited about the anti-GITR program, notably the unique and multifaceted mechanism of action and its promising safety profile," said Tony deFougerolles, Tolerx Chief Scientific Officer. "The preclinical data indicate that TRX518 has tremendous potential for enhancing anti-tumor responses, regardless of tumor type, and for also improving the effectiveness of other cancer therapies including chemotherapeutics and cancer vaccines."

About TRX518

TRX518 is an investigational immunotherapy designed to activate GITR (glucocorticoid-induced tumor necrosis factor receptor) found on multiple types of T cells and other immune cells. GITR plays a role in directing the anti-tumor immune response via a multifaceted mechanism of action that includes activating tumor antigen-specific T effector cells, abrogating the suppression induced by T regulatory cells, and activating NK cells. In preclinical studies, TRX518 achieved its effect without compromising normal immune function, and preclinical models suggest TRX518 to have a favorable safety profile. A Phase 1 clinical study of TRX518, a first-in-class anti-GITR monoclonal antibody, has been initiated to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ascending single doses of TRX518 in patients with malignant melanoma. TRX518 is designed to have activating and sustaining effects on T cells for enhancing the immune system's responses against cancer cells, including responses that may occur with TRX518 alone, as well as complementary responses in combination with other cancer therapies including vaccines. 

About Tolerx

Tolerx, Inc., a world leader in immunology for novel drug development, has a portfolio of innovative, first-in-class drug candidates to treat autoimmune diseases, d
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer
2. Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
3. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
4. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
5. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
6. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
7. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
8. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
9. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
10. Prime Therapeutics President and CEO Eric Elliott Presents Keynote Address at 2011 PCMA Managed Markets Educational Forum
11. Watson Presents Outlook for Continued Long Term Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  Diplomat, the nation,s largest ... David Dreyer to the Board of Directors on ... and will also serve as chair of the Audit ... years of accounting, financial, compliance and operating experience in ... has served as chief financial officer, chief operating officer ...
(Date:9/19/2014)... Mass. , Sept. 19, 2014  Alere Inc. ... rapid diagnostics, issued the following statement today in support ... Antibiotic-Resistant Bacteria. "As the global leader in ... for establishing a national strategy to address the serious ... to work with the Administration on initiatives to promote ...
(Date:9/19/2014)... 19, 2014 Aufgrund der ... äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die ... verfügbar unter pharmaserialisation.com , zeigt die Serialisierungsanforderungen ... in Kraft treten. Für international tätige ... um das "ob", sondern darum, "wann" sie die ...
Breaking Medicine Technology:David Dreyer Appointed to Diplomat Board of Directors 2Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2
... Trial Showed REMICADE Therapy is More Likely to Induce ... ... Oct. 6 Data presented for the first time,from the Phase ... Therapy (SONIC) may provide new insights into,the approach to care of ...
... with ... in Clinical Trials -, PHOENIX, Oct. 6 ... focused on the treatment of,obesity and other central nervous ... (naltrexone SR /,bupropion SR), successfully achieved key objectives (lowered ...
Cached Medicine Technology:New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 2New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 5New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 6New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 7New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 8Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 2Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 3Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 4Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 5
(Date:9/19/2014)... New York, NY (PRWEB) September 19, 2014 ... by PR News at the Platinum PR and Top ... Grand Hyatt in New York City. Camino received honorable ... a Shoestring Campaign” — for its work elevating Latina ... with this incredible organization and be a part of ...
(Date:9/19/2014)... of human cancers have abnormally upregulated chemical signals ... are controlled during tumor formation is not fully ... Fayngerts, PhD, both researchers in the department of ... of Medicine, University of Pennsylvania, and colleagues report ... cancer by targeting these pathways. , Lipid second ...
(Date:9/19/2014)... 2014 Hastings and Hastings, a discount accident ... industry, announces a record number of visitors to its new ... of serious injury cases as well as auto accident cases ... related accident cases and others. Having served the state of ... the test of time when it comes to dedicated and ...
(Date:9/19/2014)... with The Melanoma Genetics Consortium, GenoMEL, an international research ... Journal of the National Cancer Institute that proves ... the first time, we have established that the genes ... in the risk of developing melanoma," said lead author ... at the University of Leeds (UK). , Telomeres ...
(Date:9/19/2014)... NJ (PRWEB) September 19, 2014 Visiting ... provider of home health care, hospice and palliative care ... to ring the Opening Bell yesterday at the New ... New Jersey philanthropist and social entrepreneur to care for ... Health Group has always worked to meet the urgent ...
Breaking Medicine News(10 mins):Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:New cancer drug target involving lipid chemical messengers 2Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:Melanoma risk found to have genetic determinant 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3
... MS, ... and sharing her story of hope and determination. , ... Bayfield, WI (PRWEB) April 7, 2010 -- Hopeful climbers have begun streaming in to ... highest peak. Last year,s successful climbers whose summit of Everest also completed their ...
... ... their newest Low level laser for body sculpting. Surprisingly Zerona has also been clinically ... addition to lowering the levels of Lipoprotein (LDL). , ... Houston, TX (PRWEB) April 6, 2010 -- A ...
... ... conversations about your brand, advertising campaign, competitors or product innovations. , ... (PRWEB) April 6, 2010 -- Six ... an easy, affordable way to gather insights needed to optimize marketing strategies, increase advertising ...
... for treatment, at higher rates than expected , TUESDAY, April ... visit hospitals repeatedly in search of treatment, according to new ... of sickle cell patients who visited the hospital returned within ... the ages of 18 and 30, were especially likely to ...
... An approach designed to reduce HIV/STDs previously used ... community-based organizations (CBOs), an important component in national strategies ... "at risk" youths can be reached. , A ... tested whether a proven HIV/STD risk-reduction intervention would work ...
... work better in protecting children from flu if they included ... Louis University research has found. "Adding a second influenza ... some of the guesswork out of strain selection and help ... M.D., lead investigator and director of the Center for Vaccine ...
Cached Medicine News:Health News:Woman with MS Summits Everest and Completes the Seven Summits 2Health News:Woman with MS Summits Everest and Completes the Seven Summits 3Health News:"Zerona" Lipo-Laser Penetrates Wellness Industry for Anti-aging, Weight Loss, Body Sculpting and Cardiac Health 2Health News:"Zerona" Lipo-Laser Penetrates Wellness Industry for Anti-aging, Weight Loss, Body Sculpting and Cardiac Health 3Health News:Sickle Cell Disease Patients Seek Acute Pain Care Repeatedly 2Health News:Sickle Cell Disease Patients Seek Acute Pain Care Repeatedly 3Health News:Roll-out of proven HIV/STD risk-reduction intervention with teens by community groups successful 2Health News:Building a better flu vaccine: Add second strain of influenza B 2
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
... are offered as 1-piece or modular, in ... instruments may be customized with handles of ... insulation and flush ports. Many standard patterns ... may affect delivery times. , Please ...
... The Featured Products ... at Mediflex and are ... modular in regular or ... come equipped with insulation, ...
Medicine Products: